Virax Biolabs Group Ltd SEC filings VRAX
Virax Biolabs Group Ltd has 159 filings in SEC EDGAR's recent list, going back to Dec 27, 2021. Its latest annual report, Form 20-F, was filed on Jul 6, 2026 for the period ended Mar 31, 2026. The most recent current report (Form 6-K) was filed on Oct 29, 2026. The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 3 | Initial insider ownership | Oct 21, 2026 | Oct 5, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| 3 | Initial insider ownership | Mar 31, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 20, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| 3 | Initial insider ownership | Mar 18, 2026 | Mar 18, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 17, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 29, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 29, 2025 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 29, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 29, 2025 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 14, 2024 | — |
Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- VRAX (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Cayman Islands
- Headquarters
- Lanarkshire, United Kingdom
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1885827
- Former names
- Virax Biolabs (Cayman) Ltd (until Dec 27, 2021)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.